Literature DB >> 8547414

Hospital service utilization by HIV/AIDS patients and their management cost in a provincial genitourinary medicine department.

A Nageswaran1, G R Kinghorn, R N Shen, C J Priestley, T T Kyi.   

Abstract

The hospital management of 108 HIV/AIDS patients cared for by the genitourinary medicine department, Sheffield, UK between 1984-93 was retrospectively studied to quantify the services utilized by these patients and to detail the management costs (1993 price) of outpatient (OP) services, inpatient (IP) care, investigational services and therapeutic provisions. The services utilized and cost are presented separately for the different clinical stages of the infection and as per patient year. Of the 108 patients, 95 (88%) were males and 13 (12%) females; most males (76.8%) acquired the infection through homosexual exposure, while 46% of females acquired it heterosexually. The mean number of OP consultation per asymptomatic, symptomatic non-AIDS and AIDS patient years were 11.6, 16.4 and 32.8 respectively; the mean number of IP episodes for each of these clinical groups were 0.15, 0.83 and 3.88 with IP stays 0.7, 3.5 and 40.6 days per patient year respectively. The annual costs of OP care (45.26 pounds per consultation), drugs and investigations were, respectively 525 pounds, 213 pounds and 153 pounds per asymptomatic patient year, 742 pounds, 2097 pounds and 224 pounds per symptomatic non-AIDS patient year and 1485 pounds, 2928 pounds and 382 pounds per AIDS patient year. The average annual OP drug cost per patient year showed little change since 1988. However, in the AIDS group, contributions from differing drug classes showed significant changes; while the contribution of antiretroviral drugs fell from 80.2% of the drug cost per AIDS patient year in 1990 to 31.3% in 1993, that from antibiotics rose from 0.3% in 1990 to 26.4% in 1993 and other antivirals from 9.4% in 1988 to 22.6% in 1993. These changes were related to lower recommended daily dosage of zidovudine and to wider prescription of antibiotics for atypical mycobacterial infections and domiciliary gancyclovir for CMV infection. The costs of annual mean IP care, IP drugs, IP investigations and IP procedures per AIDS patient year were 5926 pounds (146 pounds per IP stay), 2983 pounds, 282 pounds and 145 pounds respectively. The overall management cost of one AIDS patient year was 14,131 pounds and lifetime AIDS management cost, based on a mean survival of 17 months, a little more than 20,000 pounds. The annual management cost of an asymptomatic and symptomatic non-AIDS patient year is approximately 1/14th and 1/4th of the cost of an AIDS patient year.

Entities:  

Mesh:

Year:  1995        PMID: 8547414     DOI: 10.1177/095646249500600506

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  5 in total

Review 1.  Health economics in HIV disease. A review of the European literature.

Authors:  M Youle; P Trueman; K Simpson
Journal:  Pharmacoeconomics       Date:  1999       Impact factor: 4.981

2.  Survival and treatment of AIDS patients 1984-1993: experience of a smaller east London HIV centre.

Authors:  R J Hillman; E J Beck; S Mandalia; H Satterthwaite; P A Rogers; G E Forster; B T Goh
Journal:  Genitourin Med       Date:  1997-02

Review 3.  The cost of HIV treatment and care. A global review.

Authors:  E J Beck; A H Miners; K Tolley
Journal:  Pharmacoeconomics       Date:  2001-01       Impact factor: 4.981

4.  The use and cost of HIV service provision in England in 1996. National Prospective Monitoring System (NPMS) Steering Group and NPMS Working Party on Costs.

Authors:  E J Beck; K Tolley; A Power; S Mandalia; P Rutter; J Izumi; J Beecham; A Gray; D Barlow; P Easterbrook; M Fisher; J Innes; G Kinghorn; B Mandel; A Pozniak; A Tang; D Tomlinson; I Williams
Journal:  Pharmacoeconomics       Date:  1998-12       Impact factor: 4.981

5.  Hospitalization Outcomes in Pneumocystis Pneumonia Inpatient Population: A Comparison between HIV and Non-HIV Patients.

Authors:  Sorabh Datta; Shanan Mahal; Virendrasinh Ravat; Bipin Saroha; Ehinor E Isidahome; Priya Patel
Journal:  Cureus       Date:  2018-08-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.